Melanotan I, also called afamelanotide, is a 13 amino acid linear peptide that mimics alpha-melanocyte stimulating hormone. It binds the melanocortin-1 receptor (MC1R) with greater potency than the native hormone, and it is highly selective for MC1R. This selectivity distinguishes it from melanotan II, a cyclic 7 amino acid peptide that also activates MC3, MC4, and MC5 receptors. Because melanotan I does not engage MC4R, the appetite and sexual effects associated with melanotan II are absent.

In the United States, the FDA approved afamelanotide in 2019 for erythropoietic protoporphyria (EPP) in adults, and it is also approved in Europe. EPP involves accumulation of protoporphyrin IX, a photoreactive heme-synthesis metabolite that raises oxidative stress under visible light and produces intense skin pain. The peptide is not approved for cosmetic tanning. Australian regulators issued a safety warning after finding impurities in unregulated melanotan I and II products, which are often mislabeled.

How it works

MC1R activation engages a Gs protein and adenylyl cyclase, raising intracellular cyclic AMP. Cyclic AMP drives protein kinase A, which phosphorylates CREB and induces MITF, the master transcription factor for melanocyte function. MITF upregulates tyrosinase, the rate-limiting enzyme of melanogenesis.

Signaling then diverges into independent arms. One arm produces pigment through the PKA, CREB, and MITF axis. A separate DNA repair arm works through ATR and ATM phosphorylation and activates nucleotide excision repair, supporting genome integrity after ultraviolet exposure. Additional effects include NRF2-driven antioxidant activity, reactive oxygen species scavenging, and NF-kappaB inhibition with cytokine suppression across melanocytes, leukocytes, macrophages, and dendritic cells.

Clinical evidence

Phase three trials in EPP reported reduced phototoxic pain, longer pain-free sun exposure, fewer phototoxic reactions, and improved recovery. Investigational work has examined vitiligo, where combination with narrowband UVB showed greater repigmentation than UVB alone, along with polymorphous light eruption, solar urticaria, and other dermatologic conditions. A dose-dependent reduction in ALT and bilirubin has been observed in EPP patients, attributed to anti-inflammatory action in the liver.

Long-term observation across more than 1,000 implants and several hundred patients, some with up to ten years of exposure, has not identified a melanoma signal. The approved form is a subcutaneous PLGA implant placed over the superior iliac crest, with a roughly 15 hour half-life, dosed about every two months and limited to four implants per year. The speaker notes anecdotal subcutaneous injection protocols that lack randomized controlled validation.

Key clinical points

• Melanotan I is a 13 amino acid, MC1R-selective agonist, FDA-approved for erythropoietic protoporphyria and first in its melanocortin class.
• Signaling separates into a pigmentation arm and a DNA repair arm, with added antioxidant and anti-inflammatory activity.
• Unlike melanotan II, it does not activate MC4R, so appetite and sexual effects are absent.
• Twice-yearly full-body skin exams and continued sun protection are required, with contraindications including melanoma history and premalignant lesions.
• Off-label and injectable dosing schemes remain anecdotal and call for informed consent and further evidence.